Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia

Jang-Ho CHO; Joon-Ho SHIM; Sang-Eun YOON; Hee-Jin KIM; Sun-Hee KIM; Young-Hyeh KO; Seung-Tae LEE; Kihyun KIM; Won-Seog KIM; Seok-Jin KIM.
The Korean Journal of Internal Medicine ; : 668-678, 2021.
Artículo en Inglés | WPRIM | ID: wpr-896001

Documentos relacionados

  1. Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia.
  2. Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia
  3. [Lymphoplasmacytic lymphoma: a clinicopathological and prognostic analysis of 27 cases].
  4. [Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].
  5. Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact.
  6. A prognostic index predicting survival in transformed Waldenström macroglobulinemia.
  7. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
  8. Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?
  9. Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study.
  10. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia.